Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MBX | CLUSTER | neutral | 2/10 | Two top executives (CEO and CMO) sold a total of $25K in open-market sales on May 6, 2026, one day after Q1 earnings bea | May 8, 2026 |
| SIGA | DEFA14A | neutral | 2/10 | SIGA Technologies filed a DEFA14A supplement to its 2026 proxy statement, correcting errors in Proposal 4 regarding the | May 8, 2026 |
| BFRI | PRESS-RELEASE | neutral | 1/10 | Biofrontera Inc. announced it will report its Q1 2026 results on May 14, 2026. | May 8, 2026 |
| MBX | 144 | neutral | 3/10 | Former officer Richard Bartram filed a Form 144 notice of intent to sell 10,000 MBX shares (~$379,562 at filing). The sh | May 8, 2026 |
| MRNA | 144 | neutral | 2/10 | Former director Paul Sagan filed Form 144 to sell 36,759 shares of Moderna, with an estimated value of ~$2.0 million. Th | May 8, 2026 |
| CYTK | PRESS-RELEASE | bearish | 6/10 | Cytokinetics closed an underwritten public offering of 11.3 million shares at $71.00 per share, raising approximately $8 | May 8, 2026 |
| TNGX | 8-K | neutral | 2/10 | Tango Therapeutics formalized the separation of former CFO Daniella Beckman, who was terminated without cause effective | May 8, 2026 |
| BIOA | 8-K | bullish | 7/10 | BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from $1.5M YoY) and an EPS beat of $-0.52 vs consensus $ | May 8, 2026 |
| ALLR | PRESS-RELEASE | neutral | 2/10 | Allarity Therapeutics CEO Thomas Jensen will present at Precision Medicine Forum Europe 2026 on May 11, discussing steno | May 8, 2026 |
| MBRX | 8-K | neutral | 3/10 | Moleculin Biotech announced the issuance of a Hong Kong patent (No. 40073244) covering its proprietary method of reconst | May 8, 2026 |
| CGON | 8-K | mixed | 5/10 | CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, wider than the prior year's $0.45 loss, and tot | May 8, 2026 |
| CGON | PRESS-RELEASE | neutral | 5/10 | CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, slightly wider than the $0.45 loss a year ago, | May 8, 2026 |
| BIAFW | 8-K | mixed | 5/10 | bioAffinity Technologies reported Q1 2026 revenue of $1.4M, down 27% YoY from $1.9M due to the discontinuation of unprof | May 8, 2026 |
| ASRT | 8-K | neutral | 3/10 | Assertio and Garda mutually agreed to delay the launch of the tender offer to acquire Assertio for $21.80 per share ($15 | May 8, 2026 |
| ALXO | 8-K | neutral | 5/10 | ALX Oncology reported Q1 2026 GAAP net loss of ($17.9) million, or ($0.17) per share, narrowing from ($0.58) per share i | May 8, 2026 |
| ALMR | 8-K | bullish | 8/10 | Alamar Biosciences reported Q1 2026 revenue of $26.0M, a 99% YoY increase, driven by 178% consumable revenue growth. Net | May 8, 2026 |
| HUMA | PRESS-RELEASE | neutral | 1/10 | Humacyte, Inc announced it will report its Q1 2026 results on May 13, 2026. | May 8, 2026 |
| BCDA | 8-K | bullish | 6/10 | BioCardia announced FDA alignment on two regulatory pathways for its Helix Transendocardial Delivery Catheter System: si | May 8, 2026 |
| ALXO | PRESS-RELEASE | bearish | 6/10 | ALX Oncology reported Q1 2026 GAAP EPS of -$0.17, significantly missing the consensus estimate of -$0.16 (a -6.25% miss) | May 8, 2026 |
| ALMR | PRESS-RELEASE | bullish | 7/10 | Alamar Biosciences reported Q1 2026 revenue of $26.0M, up 99% YoY from $13.1M, driven by 178% consumable growth and 78% | May 8, 2026 |
| CRLBF | 6-K | bearish | 6/10 | Cresco Labs reported Q1 2026 revenue of $151.3M, down 8.7% YoY from $165.8M, with a net loss of $17.0M (vs. $15.2M loss | May 8, 2026 |
| TRAW | PRESS-RELEASE | neutral | 4/10 | Traws Pharma announced plans to develop clinical candidates for hantavirus treatment following a recent outbreak linked | May 8, 2026 |
| PSTV | PRESS-RELEASE | bullish | 6/10 | Plus Therapeutics presented a plenary session at the 2026 AANS Annual Meeting highlighting Phase 1 ReSPECT-LM data for R | May 8, 2026 |
| SCNI | 6-K | bearish | 7/10 | Scinai Immunotherapeutics filed audited FY2025 financials for its newly acquired CDMO subsidiary, Scinai Biopharma Servi | May 8, 2026 |
| HYPD | PRESS-RELEASE | bearish | 6/10 | Hyperion DeFi closed a public offering of 2,777,778 shares at $3.60 per share, raising approximately $10.0 million in gr | May 8, 2026 |
| BOLD | PRESS-RELEASE | bearish | 6/10 | Boundless Bio reported Q1 2026 net loss of $13.6M ($0.60/share), wider than the consensus estimate of $0.56 loss per sha | May 8, 2026 |
| TVRD | PRESS-RELEASE | neutral | 4/10 | Tvardi Therapeutics reported Q1 2026 EPS of -$0.73, missing consensus of -$0.72 by 1.4% (in-line), with no revenue. The | May 8, 2026 |
| KPHMW | 8-K | neutral | 3/10 | Kiora Pharmaceuticals reported a Q1 2026 net loss of $2.4M, wider than the $2.2M loss in Q1 2025, driven by higher R&D a | May 8, 2026 |
| BOLD | 8-K | neutral | 3/10 | Boundless Bio reported Q1 2026 results with a net loss of $13.6M, narrower than the $15.8M loss in Q1 2025, driven by lo | May 8, 2026 |
| ANIP | 8-K | bullish | 8/10 | ANI Pharmaceuticals reported Q1 2026 revenue of $237.5M (+20.5% YoY) and GAAP diluted EPS of $1.28, beating consensus es | May 8, 2026 |